HomeHealthZimmer Biomet Announces Quarterly Dividend for Third Quarter of 2022

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2022

Published on

<br /> Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2022<br />

PR Newswire



WARSAW, Ind.


,


Aug. 26, 2022


/PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2022. The cash dividend of

$0.24

per share is payable on or about

October 31, 2022

to stockholders of record as of the close of business on

September 30, 2022

.


About the Company

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit

www.zimmerbiomet.com

or follow Zimmer Biomet on Twitter at

www.twitter.com/zimmerbiomet

.



Media



Investors


Meredith Weissman


Keri Mattox


703-346-3127


215-275-2431



[email protected]



[email protected]

Cision
View original content to download multimedia:

https://www.prnewswire.com/news-releases/zimmer-biomet-announces-quarterly-dividend-for-third-quarter-of-2022-301612824.html

SOURCE Zimmer Biomet Holdings, Inc.

rt Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2022

Featured image: © lbrfzhjpf.gmail.com

Disclaimer

Latest News

BD, CerTest Biotec Announce US Commercial Launch of Monkeypox Assay

BD, CerTest Biotec Announce US Commercial Launch of...

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Creative Medical Technology Announces Peer Reviewed Publication of...

Centene Subsidiary Selected to Continue Serving Nebraska’s Medicaid Managed Care Members

Centene Subsidiary Selected to Continue Serving Nebraska's Medicaid...

More like this

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi (CSE:OPTI)(OTCQX:OPTHF)(FRA:8BN) aiming to become the first vertically integrated psychedelics firm to formulate and...

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

The exclusive license allows GSK to commercialize tebipenem HBr in...

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

– Positions Company for leadership in AI-powered drug discovery – ...

CVS Health reports progress against goal to reduce suicide attempts among Aetna members 20% by 2025

CVS Health reports progress against goal to reduce...